LIMN net incomeQ2 2026-$1.41M
LIMN net income was -$1.41M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $113.3K a year earlier. For the full fiscal 2025 it was -$10.21M, compared with -$3.55M in fiscal 2024.
Liminatus Pharma Inc. (LIMN) financials
For the twelve months ended Jun 30, 2026, Liminatus Pharma Inc. reported -$12.52M of net income.
- Net income, TTM
- -$12.52M
- Cash
- $3.02M
- Market cap
- $3.6M
FY2024FY2025
LIMN revenue and earnings growth
LIMN EPSQ2 2026-$0.03
LIMN diluted EPS was -$0.03 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.43, compared with -$0.20 in fiscal 2024.
LIMN free cash flowQ4 2025-$386.8K
LIMN free cash flow was -$386.8K in fiscal Q4 2025 (ended Dec 31, 2025). For the full fiscal 2025 it was -$9.98M.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Research and development | - | $2.69M |
| Selling, general and admin | $2.97M | $644.6K |
| Operating income | -$2.97M | -$3.33M |
| Interest expense | $215.9K | $338.9K |
| Net income | -$10.21M | -$3.55M |
| EPS, basic | -$0.43 | -$0.20 |
| EPS, diluted | -$0.43 | -$0.20 |
| Diluted shares | 23.8M | 17.5M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $337.7K | $56.3K |
| Current assets | $500.6K | $5.28M |
| Total assets | $512.8K | $5.41M |
| Current liabilities | $10.30M | $24.75M |
| Short-term debt | $1.44M | $19.97M |
| Total liabilities | $10.33M | $24.75M |
| Shareholders' equity | -$9.81M | -$19.34M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$9.96M | -$1.45M |
| Capital expenditures | $13.1K | - |
| Free cash flow | -$9.98M | - |
| Investing cash flow | -$788.1K | -$2.85M |
| Financing cash flow | $11.03M | $3.92M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $600.0K | $400.0K | - | - | - | - | $0 | $357.1K | $714.1K | $1.61M |
| Selling, general and admin | $778.9K | $700.9K | $884.2K | $701.2K | $1.12M | $264.2K | $167.1K | $186.1K | $195.1K | $96.4K |
| Operating income | -$1.38M | -$1.10M | -$884.2K | -$701.2K | -$1.12M | -$264.2K | -$167.1K | -$543.1K | -$909.2K | -$247 |
| Interest expense | $18.8K | $18.6K | $19.1K | $19.1K | $62.3K | $115.5K | $106.2K | $92.7K | $77.2K | $62.8K |
| Net income | -$1.41M | -$1.12M | -$8.17M | -$1.82M | $113.3K | -$327.5K | -$229.8K | -$601.4K | -$961.2K | -$1.75M |
| EPS, basic | -$0.03 | -$0.03 | - | -$0.07 | $0.00 | -$0.02 | - | -$0.03 | -$0.05 | -$2.47 |
| EPS, diluted | -$0.03 | -$0.03 | - | -$0.07 | $0.00 | -$0.02 | - | -$0.03 | -$0.05 | -$2.47 |
| Diluted shares | 48.4M | 36.0M | - | 27.0M | 23.3M | 17.5M | - | 17.5M | 17.5M | 100 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.02M | $1.91M | $337.7K | $724.5K | $1.34M | $0 | $56.3K | - | - | $0 |
| Current assets | $3.39M | $2.78M | $500.6K | $1.20M | $1.78M | - | $5.28M | - | - | - |
| Total assets | $3.40M | $2.79M | $512.8K | $1.34M | $1.91M | - | $5.41M | - | - | - |
| Current liabilities | $3.04M | $2.89M | $10.30M | $2.86M | $10.52M | - | $24.75M | - | - | - |
| Short-term debt | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | - | $19.97M | - | - | - |
| Total liabilities | $3.10M | $2.92M | $10.33M | $2.99M | $10.72M | $1.1K | $24.75M | - | - | - |
| Shareholders' equity | $300.6K | -$132.6K | -$9.81M | -$1.65M | -$8.81M | -$19.67M | -$19.34M | -$19.11M | -$18.51M | -$17.55M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$970.0K | -$2.02M | -$386.8K | -$600.6K | -$8.82M | -$159.4K | -$140.7K | -$206.1K | -$1.10M | $0 |
| Capital expenditures | - | - | $0 | - | - | - | - | - | - | - |
| Free cash flow | - | - | -$386.8K | - | - | - | - | - | - | - |
| Investing cash flow | - | - | $0 | -$13.1K | -$200.0K | -$575.0K | -$550.0K | -$800.0K | - | - |
| Financing cash flow | $2.08M | $3.59M | $0 | $0 | $10.32M | $713.0K | $700.0K | $1.02M | - | - |
Key ratios
Source: XBRL data Liminatus Pharma Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
LIMN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| LIMN | - | - | -$12.52M | - | $3.6M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
LIMN FAQ
4 questionsIs LIMN profitable?
No. Liminatus Pharma Inc. reported a net loss of $12.52M for the twelve months ended Jun 30, 2026.How much cash and debt does LIMN have?
Liminatus Pharma Inc. reported $3.02M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did LIMN last report financial results?
The latest statements here come from Liminatus Pharma Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this LIMN financial data come from?
Quantisnow builds these statements from the structured XBRL data Liminatus Pharma Inc. files with the SEC. It is provided for information only and is not investment advice.